Scholarlink

Background <p>A two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of INO-4800.</p> Methods <p>Healthy adults who received two doses of INO-4800 (1.0&#xa0;mg or 2.0&#xa0;mg) at least 12 months ago in a previous phase 2 trial were eligible for this booster study, conducted in Danyang, Jiangsu Province, China. Eligible participants were stratified by primary vaccination dose (1.0&#xa0;mg or 2.0&#xa0;mg) and age group (18–59 years or ≥ 60 years), and subsequently randomized in a 1:1 ratio to receive a third dose of INO-4800 or placebo at the same dosage as previously administered. The primary immunogenicity endpoint was the geometric mean concentrations (GMCs) of spike-binding antibodies on day 14 post-booster. The primary safety endpoint was the occurrence of adverse reactions within 14 days.</p> Results <p>Between December 20 and 23, 2021, 200 eligible participants were enrolled. 100 eligible participants who received two doses of 2.0&#xa0;mg INO-4800 were randomly assigned (1:1) to receive a third dose of 2.0&#xa0;mg INO-4800 (<i>n</i> = 50) or 2.0&#xa0;mg placebo (<i>n</i> = 50). Another 100 eligible participants who received two doses of 1.0&#xa0;mg INO-4800 were randomly assigned (1:1) to receive a third dose of 1.0&#xa0;mg INO-4800 (<i>n</i> = 50) or 1.0&#xa0;mg placebo (<i>n</i> = 50). On day 14 post-booster, the GMCs of spike-binding antibodies were significantly higher in 2.0&#xa0;mg INO-4800 group ( 260.1 BAU/mL) compared to placebo group (2.8 BAU/mL, <i>p</i> &lt; 0.001), and in 1.0&#xa0;mg INO-4800 group (104.2 BAU/mL) compared to placebo group (2.5 BAU/mL, <i>p</i> &lt; 0.001). The most common local reactions were injection site redness, occurring at rate of 16.0% in the INO-4800 groups.All adverse reactions were mild to moderate in severity and occurred within 14 days post-booster. No vaccine related serious adverse events were reported.</p> Conclusions <p>The booster regimen of one dose INO-4800 is safe and modestly immunogenic in individuals who previously received a two- dose regimen of INO-4800, with the 2.0&#xa0;mg INO-4800 demonstrating superior immunogenicity compared to the 1.0&#xa0;mg INO-4800.</p> Trial registration <p><a href="http://www.chictr.org.cn">www.chictr.org.cn</a>, identifier is ChiCTR2100054324.(December 13 2021).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月25日

查看全文
  • Aihua Yao,
  • Siyue Jia,
  • Xin Cheng,
  • Hongxing Pan,
  • Zhijian Wang,
  • Haitao Yang,
  • Yu Xia,
  • Jianfang Xu,
  • Xuefen Huai,
  • Danjing Leng,
  • Ming Xu,
  • Jiarong Wang,
  • Gan Zhao,
  • Bin Wang,
  • Jingxin Li

摘要

Background

A two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of INO-4800.

Methods

Healthy adults who received two doses of INO-4800 (1.0 mg or 2.0 mg) at least 12 months ago in a previous phase 2 trial were eligible for this booster study, conducted in Danyang, Jiangsu Province, China. Eligible participants were stratified by primary vaccination dose (1.0 mg or 2.0 mg) and age group (18–59 years or ≥ 60 years), and subsequently randomized in a 1:1 ratio to receive a third dose of INO-4800 or placebo at the same dosage as previously administered. The primary immunogenicity endpoint was the geometric mean concentrations (GMCs) of spike-binding antibodies on day 14 post-booster. The primary safety endpoint was the occurrence of adverse reactions within 14 days.

Results

Between December 20 and 23, 2021, 200 eligible participants were enrolled. 100 eligible participants who received two doses of 2.0 mg INO-4800 were randomly assigned (1:1) to receive a third dose of 2.0 mg INO-4800 (n = 50) or 2.0 mg placebo (n = 50). Another 100 eligible participants who received two doses of 1.0 mg INO-4800 were randomly assigned (1:1) to receive a third dose of 1.0 mg INO-4800 (n = 50) or 1.0 mg placebo (n = 50). On day 14 post-booster, the GMCs of spike-binding antibodies were significantly higher in 2.0 mg INO-4800 group ( 260.1 BAU/mL) compared to placebo group (2.8 BAU/mL, p < 0.001), and in 1.0 mg INO-4800 group (104.2 BAU/mL) compared to placebo group (2.5 BAU/mL, p < 0.001). The most common local reactions were injection site redness, occurring at rate of 16.0% in the INO-4800 groups.All adverse reactions were mild to moderate in severity and occurred within 14 days post-booster. No vaccine related serious adverse events were reported.

Conclusions

The booster regimen of one dose INO-4800 is safe and modestly immunogenic in individuals who previously received a two- dose regimen of INO-4800, with the 2.0 mg INO-4800 demonstrating superior immunogenicity compared to the 1.0 mg INO-4800.

Trial registration

www.chictr.org.cn, identifier is ChiCTR2100054324.(December 13 2021).